Amundi
RLAY icon

Amundi’s Relay Therapeutics RLAY Stock Holding History

Amundi’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Sell
17,726
-3,655
-17% -$53.1K ﹤0.01% 1814
2026
Q1 		$213K Buy
+21,381
New +$191K ﹤0.01% 1860
2025
Q2 		– Sell
-36
Closed -$82 – 2073
2025
Q1 		$82 Sell
36
-164
-82% -$643 ﹤0.01% 2174
2024
Q4 		$966 Buy
+200
New +$1.09K ﹤0.01% 2027
2024
Q2 		– Sell
-7,775
Closed -$47.5K – 2032
2024
Q1 		$47.5K Hold
7,775
– – ﹤0.01% 1846
2023
Q4 		$92.3K Buy
+7,775
New +$65.6K ﹤0.01% 1792

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Amundi's RLAY Position: Q2 2026 in Review

Amundi reduced its Relay Therapeutics (RLAY) stake by 17% in Q2 2026, selling an estimated $53.1K and leaving 17,726 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #1814.

Amundi first reported a position in RLAY in Q4 2023 and has held it in 6 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Amundi held 17,726 shares of Relay Therapeutics worth $332K as of Q2 2026.
  • Amundi sold 3,655 Relay Therapeutics shares in Q2 2026, an estimated $53.1K.
  • Relay Therapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1814 holding.
  • Amundi first reported a position in Relay Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.